麝香保心丸预防冠心病PCI术后再狭窄的临床疗效观察

Clinical efficacy of SXBXW to Prevent the Restenosis After PCI in Patient with Coronary Artery Disease

目的:探讨麝香保心丸预防冠心病经皮腔内冠状动脉介入治疗(PCI)术后再狭窄的临床效果。方法:对176例冠心病经PCI治疗的病人分为:对照组(常规治疗组)和治疗组(常规治疗加用麝香保心丸组),比较两组之间PCI术后的心绞痛、临床再狭窄和造影再狭窄发生人数的差异。结果:治疗组心绞痛和临床再狭窄人数明显少于对照组(P(0.005);造影再狭窄发生人数治疗组也少于对照组(P(0.05)。结论:SXBXW具有预防PCI术后再狭窄的作用。

Objective： To observe the clinical efficacy ofShexiang Baoxin Wan （SXBXW） to prevent the restenosis after PCI in patients with Coronary artery disease（CAD）. Methods： 176 patients with CAD treated by PCI were randomly divided into two group：the control group： with general treated after PCI;the trial group ： with general treated and SXBXW after PCI, and then to compare the difference between the two groups on the number of patients with angina, the clinical restenosis and restenosis of coronary arteriongraphy. Results ： The number of bath patients of angina and the clinical restenosis in trail group were significant lower than that of patients in control group （ P 〈 0.005 ）, The number of patients of restenosis of coronary arteriongraphy in trail group was also significant lower than that of patients in control group （ P 〈 0. 05）. Conclusion： SXBXW can prevent the restenosis after PCI in patients with CAD.